Annual report
7129.TEDINET S100OG2Y
Period2021-10-01 → 2022-03-31
Filed2022-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 38
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.5bn | 2021-10-01 → 2022-03-31 | Cons. | Net sales |
| Operating income | ¥186m | 2021-10-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥190m | 2021-10-01 → 2022-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥534m | 2021-10-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥292m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥292m | 2021-10-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥14.2bn | at 2022-03-31 | Cons. | Assets |
| Total liabilities | ¥11.0bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.2bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.0bn | at 2021-09-30 | Cons. | Net assets |
| Cash and deposits | ¥1.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥691m | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥919m | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.5bn | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥2.0bn | 2021-10-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥117.49 | 2021-10-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥116.61 | 2021-10-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,287.13 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 22.5% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.4% | 2021-10-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,752 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥116m | 2021-10-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥52m | 2021-10-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥62m | 2021-10-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥3.1bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥71m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.1bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥3m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥24.86 | 2021-10-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥24.68 | 2021-10-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥17 | 2021-10-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,232.94 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 97.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.0% | 2021-10-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,488,300 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-10-01 → 2022-03-31 | ¥237,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-10-01 → 2022-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 22 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-10-01 → 2022-03-31 | ¥932m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-10-01 → 2022-03-31 | ¥905m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥27m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥165m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-10-01 → 2022-03-31 | ¥39m |
| Reconciling Itemsreconciling | capex | 2021-10-01 → 2022-03-31 | ¥218m |
| Reconciling Itemsreconciling | depreciation | 2021-10-01 → 2022-03-31 | ¥42m |
| Reconciling Itemsreconciling | revenue | 2021-10-01 → 2022-03-31 | −¥27m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-10-01 → 2022-03-31 | −¥27m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-03-31 | −¥798m |
| Medicine Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥175m |
| Medicine Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥68m |
| Medicine Businessreportable segment | employees | at 2022-03-31 | 194 pure |
| Medicine Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥8.8bn |
| Medicine Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥8.8bn |
| Medicine Businessreportable segment | segment assets | at 2022-03-31 | ¥2.9bn |
| Medicine Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥559m |
| Nursing Care Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥69m |
| Nursing Care Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥55m |
| Nursing Care Businessreportable segment | employees | at 2022-03-31 | 290 pure |
| Nursing Care Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | segment assets | at 2022-03-31 | ¥1.2bn |
| Nursing Care Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥25m |
| Nurturing Businessreportable segment | capex | 2021-10-01 → 2022-03-31 | ¥2.6bn |
| Nurturing Businessreportable segment | depreciation | 2021-10-01 → 2022-03-31 | ¥307m |
| Nurturing Businessreportable segment | employees | at 2022-03-31 | 1192 pure |
| Nurturing Businessreportable segment | revenue | 2021-10-01 → 2022-03-31 | ¥6.4bn |
| Nurturing Businessreportable segment | revenue external | 2021-10-01 → 2022-03-31 | ¥6.4bn |
| Nurturing Businessreportable segment | segment assets | at 2022-03-31 | ¥7.8bn |
| Nurturing Businessreportable segment | segment profit | 2021-10-01 → 2022-03-31 | ¥362m |
| —segment total | capex | 2021-10-01 → 2022-03-31 | ¥2.9bn |
| —segment total | depreciation | 2021-10-01 → 2022-03-31 | ¥430m |
| —segment total | revenue | 2021-10-01 → 2022-03-31 | ¥18.6bn |
| —segment total | revenue external | 2021-10-01 → 2022-03-31 | ¥18.6bn |
| —segment total | segment assets | at 2022-03-31 | ¥12.0bn |
| —segment total | segment profit | 2021-10-01 → 2022-03-31 | ¥946m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-10-01 → 2022-03-31 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-10-01 → 2022-03-31 | ¥434m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-10-01 → 2022-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-10-01 → 2022-03-31 | ¥19.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-10-01 → 2022-03-31 | ¥27m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥12.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-10-01 → 2022-03-31 | ¥985m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 794
| Item | Context | Value | Unit |
|---|---|---|---|
| Subsidy income on facilities ei | CurrentYearDuration_TotalOfReportableSegmentsAndOthersMember | 442841000 | JPY |
| Subsidy income on facilities ei | CurrentYearDuration_ReconcilingItemsMember | 449000 | JPY |
| Subsidy income on facilities ei | CurrentYearDuration | 443291000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E36714-000MedicineBusinessReportableSegmentMember | - | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E36714-000NursingCareBusinessReportableSegmentMember | 50177000 | JPY |
| Impairment loss el | CurrentYearDuration_jpcrp030000-asr_E36714-000NurturingBusinessReportableSegmentMember | 6850000 | JPY |
| Impairment loss el | CurrentYearDuration_ReportableSegmentsMember | 57027000 | JPY |
| Impairment loss el | CurrentYearDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | - | JPY |
| Impairment loss el | CurrentYearDuration_UnallocatedAmountsAndEliminationMember | 56683000 | JPY |
| Impairment loss el | CurrentYearDuration | 113711000 | JPY |
| Goodwill | CurrentYearInstant_jpcrp030000-asr_E36714-000MedicineBusinessReportableSegmentMember | - | JPY |
| Goodwill | CurrentYearInstant_jpcrp030000-asr_E36714-000NursingCareBusinessReportableSegmentMember | - | JPY |
| Goodwill | CurrentYearInstant_jpcrp030000-asr_E36714-000NurturingBusinessReportableSegmentMember | 351691000 | JPY |
| Goodwill | CurrentYearInstant_ReportableSegmentsMember | 351691000 | JPY |
| Goodwill | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | - | JPY |
| Goodwill | CurrentYearInstant_UnallocatedAmountsAndEliminationMember | - | JPY |
| Goodwill | CurrentYearInstant | 351691000 | JPY |
| Cash and deposits | CurrentYearInstant_NonConsolidatedMember | 2619000 | JPY |
| Accounts receivable other | CurrentYearInstant_NonConsolidatedMember | 106267000 | JPY |
| Other ca | CurrentYearInstant_NonConsolidatedMember | 14484000 | JPY |
| Current assets | CurrentYearInstant_NonConsolidatedMember | 123370000 | JPY |
| Stocks of subsidiaries and affiliates | CurrentYearInstant_NonConsolidatedMember | 3005123000 | JPY |
| Deferred tax liabilities allowance investments and other assets | CurrentYearInstant_NonConsolidatedMember | 10117000 | JPY |
| Investments and other assets | CurrentYearInstant_NonConsolidatedMember | 3015241000 | JPY |
| Noncurrent assets | CurrentYearInstant_NonConsolidatedMember | 3015241000 | JPY |
| Assets | CurrentYearInstant_NonConsolidatedMember | 3138611000 | JPY |
| Short term loans payable | CurrentYearInstant_NonConsolidatedMember | 40300000 | JPY |
| Accounts payable other | CurrentYearInstant_NonConsolidatedMember | 27212000 | JPY |
| Income taxes payable | CurrentYearInstant_NonConsolidatedMember | 1688000 | JPY |
| Other cl | CurrentYearInstant_NonConsolidatedMember | 1546000 | JPY |
| Current liabilities | CurrentYearInstant_NonConsolidatedMember | 70746000 | JPY |
| Liabilities | CurrentYearInstant_NonConsolidatedMember | 70746000 | JPY |
| Capital stock | CurrentYearInstant_NonConsolidatedMember | 300550000 | JPY |
| Legal capital surplus | CurrentYearInstant_NonConsolidatedMember | 550000 | JPY |
| Other capital surplus | CurrentYearInstant_NonConsolidatedMember | 2705123000 | JPY |
| Capital surplus | CurrentYearInstant_NonConsolidatedMember | 2705673000 | JPY |
| Retained earnings brought forward | CurrentYearInstant_NonConsolidatedMember | 61704000 | JPY |
| Retained earnings | CurrentYearInstant_NonConsolidatedMember | 61704000 | JPY |
| Treasury stock | CurrentYearInstant_NonConsolidatedMember | -63000 | JPY |
| Shareholders equity | CurrentYearInstant_NonConsolidatedMember | 3067865000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember | 3067865000 | JPY |
| Liabilities and net assets | CurrentYearInstant_NonConsolidatedMember | 3138611000 | JPY |
| Trademark fee income rev oa | CurrentYearDuration_NonConsolidatedMember | 46262000 | JPY |
| Dividends from subsidiaries and affiliates rev oa | CurrentYearDuration_NonConsolidatedMember | 69588000 | JPY |
| Operating revenue1 | CurrentYearDuration_NonConsolidatedMember | 115850000 | JPY |
| Operating expenses | CurrentYearDuration_NonConsolidatedMember | 63787000 | JPY |
| Operating income | CurrentYearDuration_NonConsolidatedMember | 52063000 | JPY |
| Interest income noi | CurrentYearDuration_NonConsolidatedMember | 0 | JPY |
| Other noi | CurrentYearDuration_NonConsolidatedMember | 0 | JPY |
| Non operating income | CurrentYearDuration_NonConsolidatedMember | 0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |